Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Palmitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 6/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | EP300 | Q09472 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | RAD52 | P43351 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KDM1A | O60341 | 4/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | RAC1 | P63000 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.81 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.79 |
| ▸ | MAOB | P27338 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitine SCHEMBL29766942 | 1.00 | CYP3A4 (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL29376263 | 1.00 | CYP3A4 (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL3321462 | 0.99 | ACHE (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL29424483 | 0.99 | ACHE (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL562120 | 0.99 | CYP3A4 (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL29350054 | 0.99 | CYP3A4 (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL29471136 | 0.99 | CYP3A4 (1.00) | CYP3A4EP300MAPTRAD52KDM4E | |
| Palmitine SCHEMBL2445279 | 0.98 | CYP3A4 (0.98) | CYP3A4EP300MAPTRAD52KDM4E | |
| SCHEMBL27137965 | 0.92 | CYP3A4 (0.87) | CYP3A4EP300MAPTRAD52KDM4E | |
| SCHEMBL27147420 | 0.91 | CYP3A4 (0.85) | CYP3A4EP300MAPTRAD52KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241337-A1 | PREPARING TISSUES FOR DELIVERY OF THERAPEUTIC AND DIAGNOSTIC AGENTS AND DELIVERING THE AGENTS | THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEWYORK (US) | 2022-08-04 | — | — | US | claimed |
| US-20200095627-A1 | MOLECULAR SENSORS AND USES THEREOF | NEW YORK UNIVERSITY | 2020-03-26 | — | — | US | claimed |
| CN-104561179-A | Microbial secondary metabolite palmatine hydrochloride and application thereof | UNIV YUNNAN AGRICULTURAL | 2015-04-29 | — | — | CN | claimed |
| US-20130237556-A1 | BERBERINE ALKALOID AS A MEDICAMENT FOR PREVENTION AND TREATMENT OF NEURAL DISEASE | HONG KONG BAPTIST UNIVERSITY (HK) | 2013-09-12 | — | — | US | claimed |
| WO-2012081776-A1 | COMPOSITION COMPRISING AN EXTRACT OF PHELLODENDRI CORTEX FOR THE PREVENTION OR TREATMENT OF PANCREATITIS. | YD LIFE SCIENCE CO., LTD (KR) | 2012-06-21 | — | — | WO | claimed |
| EP-2361625-A1 | Methods and compositions for the treatment of hyperlipidemia | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2011-08-31 | — | — | EP | claimed |
| US-20110158932-A1 | Methods And Compositions For The Treatment of Hyperlipidemia | ABBOTT LABORATORIES | 2011-06-30 | — | — | US | claimed |
| EP-2185521-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | Exonhit Therapeutics SA (FR) | 2010-05-19 | — | — | EP | claimed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | claimed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | claimed |
| EP-2014651-A1 | Compounds and methods for modulating Rho GTPases | Exonhit Therapeutics SA (FR) | 2009-01-14 | — | — | EP | claimed |
| EP-1796666-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2008-03-19 | — | — | EP | claimed |
| CN-101102768-A | Method and composition for the treatment of hyperlipidemia | MEDICINE AND BIOENGINEERING IN (CN) | 2008-01-09 | — | — | CN | claimed |
| EP-1796666-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | Institute of Medicinal Biotechnology, Chinese Acadamy of Medical Sciences (CN) | 2007-06-20 | — | — | EP | claimed |
| US-20060223838-A1 | Methods and compositions for the treatment of hyperlipidemia | INSTITUTE OF MEDICINAL BIOTECHNOLOGY (CN) | 2006-10-05 | — | — | US | claimed |
| WO-2006029577-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INST MEDICINAL BIOTECHNOLOGY (CN) | 2006-05-26 | — | — | WO | claimed |
| WO-2006029577-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERLIPIDEMIA | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2006-03-23 | — | — | WO | claimed |
| CN-117143017-B | Method for constructing isoquinoline compound based on aryl migration strategy, hole transport material molecule and preparation method thereof, perovskite solar cell and preparation method thereof | 广东工业大学 | 2026-05-19 | — | — | CN | disclosed |
| US-4980344-A | Compositions for improving circulatory performance | MAROKO, ANDREW | 1990-12-25 | — | — | US | disclosed |
| US-4749708-A | Composition for improving circulatory performance | MAROKO, ANDREW | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110158932-A1 | Methods And Compositions For The Treatment of Hyperlipidemia | PCSK9, APOB, LDLR | ACHE 69/4885CHRM1 2853/4885CYP3A4 4334/4885 |
| US-20130237556-A1 | BERBERINE ALKALOID AS A MEDICAMENT FOR PREVENTION AND TREATMENT OF NEURAL DISEASE | APP, PSEN1, BACE1 | ACHE 22/4885CHRM1 1668/4885CYP3A4 4422/4885 |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | ACHE 4129/4885CHRM1 3150/4885CYP3A4 4571/4885 |
| US-20060223838-A1 | Methods and compositions for the treatment of hyperlipidemia | PCSK9, APOB, LDLR | ACHE 69/4885CHRM1 2853/4885CYP3A4 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.